The discovery that 2-DG, a glycolysis inhibitor, significantly inhibits the growth of STBD1 low-expressing cancer cells, indicates that targeting glycolysis could represent an effective personalized targeting strategy for the patients with STBD1 low-expressing tumors (Fig. 6h). This evidence concerns the gene STBD1 and cancer.